Pfizer (BSP:PFIZ34) Change In Payables And Accrued Expense : R$0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Pfizer Change In Payables And Accrued Expense?

Pfizer's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was R$0 Mil. It means Pfizer's Accounts Payable & Accrued Expense stayed the same from Sep. 2023 to Dec. 2023 .

Pfizer's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was R$-1,470 Mil. It means Pfizer's Accounts Payable & Accrued Expense declined by R$1,470 Mil from Dec. 2022 to Dec. 2023 .

Pfizer Change In Payables And Accrued Expense Historical Data

The historical data trend for Pfizer's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer Change In Payables And Accrued Expense Chart

Pfizer Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

-1,399.64

1,816.08

7,023.39

6,247.27

-1,469.94

Pfizer Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Pfizer Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$0 Mil.

Pfizer Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Pfizer's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Pfizer (BSP:PFIZ34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (BSP:PFIZ34) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

PFE:USA PFE:Peru PFE:Mexico PFE_KZ:Kazakhstan 1PFE:Italy PFEd:UK 0Q1N:UK PFE:Germany PFE:Chile PFE:Canada PFE:Austria PFE:Argentina

Address

66 Hudson Boulevard East, New York, NY, USA, 10001-2192

Website

https://www.pfizer.com

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Pfizer (BSP:PFIZ34) Headlines

No Headlines